Vincent Valentine, MD
Critical Care Medicine · Baton Rouge, LANPI 1972530608
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 44.0% of the total. Reporting peaked in 2019 at $3,697 and has fallen 89.2% since, to $399 in 2025.
Across 71 payments — averaging $84.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$3K
- Insmed, Inc.$579
- La Jolla Pharmaceutical Company$354
- United Therapeutics Corporation$323
- AbbVie$253
- Mallinckrodt Hospital Products Inc.$250
- plus $2K from 22 others
What the payments were for
- Consulting fees$3336%
- Speaking & faculty fees$2,00033%
- Travel & lodging$5159%
- Food & beverage$3,15053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 3 | $2,638 |
| Insmed, Inc. | 3 | $579 |
| La Jolla Pharmaceutical Company | 3 | $354 |
| United Therapeutics Corporation | 14 | $323 |
| AbbVie(2 entities) | 5 | $253 |
| Mallinckrodt Hospital Products Inc. | 2 | $250 |
| AstraZeneca | 3 | $231 |
| Paragonix Technologies, Inc. | 3 | $160 |
| Astellas Pharma US Inc | 2 | $145 |
| Alcresta Therapeutics, Inc. | 2 | $142 |
| Eurofins Viracor, LLC | 1 | $123 |
| Actelion Pharmaceuticals US, Inc. | 5 | $113 |
| Amgen | 1 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Impulse Dynamics (USA) Inc. | 1 | $68 |
| Mylan Specialty L.p. | 2 | $65 |
| Boehringer Ingelheim | 4 | $54 |
| Baxter Healthcare | 2 | $51 |
| Shionogi Inc | 2 | $49 |
| Astellas Pharma Global Development | 1 | $44 |
| Fresenius USA Marketing, Inc. | 1 | $36 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Merck | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Pfizer | 1 | $14 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,998 in reported general payments places this provider in the 75th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Baton Rouge
- Abdulla Majid-MoosaBaton Rouge$202K
- Ahmad SharayahBaton Rouge$12K
- Ronald FieldsBaton Rouge$11K
- Merissa BraudBaton Rouge$8K
- James VermaelenBaton Rouge$8K
- Mostafa AboubakrBaton Rouge$6K
- James FordBaton Rouge$6K
- Daniel ReesBaton Rouge$4K
- Owen StellBaton Rouge$3K
- Dena LandryBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.